Hyderabad, India – April 7, 2025 – LAXAI, a leading Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in small molecules, today announced the appointment of Dr. DA Jeyaraj as the new President of LAXAI Discovery Services (LDS).
Dr. Jeyaraj brings over 22 years of extensive experience in medicinal chemistry and drug discovery, having held prominent leadership roles at renowned organizations such as Eurofins Advinus, Jubilant Biosys, and GVK BIO. His global experience includes working with prestigious pharmaceutical industries such as Novartis Institute for Tropical Diseases (NITD) in Singapore, Experimental Therapeutic Centre (ETC) in Singapore, and Semaia Pharmaceuticals in Germany.
His expertise in managing multidisciplinary teams and driving innovative drug discovery projects will be instrumental in advancing Laxai’s mission to deliver cutting-edge solutions in the pharmaceutical industry.
Dr. Jeyaraj’s impressive track record includes the successful development of multiple preclinical and clinical candidates across various therapeutic areas, including oncology, infectious diseases, metabolic disorders, and CNS. With 38 patents and numerous publications in peer-reviewed journals, his contributions to the field are well-recognized and respected globally.
Mr. Vamsi Maddipatala, Managing Director of LAXAI, has expressed his enthusiasm for Dr. Jeyaraj’s appointment, stating, “We are delighted to welcome Dr. D. A. Jeyaraj to the LAXAI family. His vast experience and proven leadership in drug discovery will be invaluable as we continue to expand our capabilities and deliver innovative solutions to our clients. Dr. Jeyaraj’s vision and expertise align perfectly with our commitment to excellence and our mission to advance drug discovery and development.”
Dr. Jeyaraj commented on his new role, “I am excited to join LAXAI and lead the talented team at LDS. LAXAI’s dedication to innovation and quality in drug discovery is truly inspiring, and I look forward to contributing to the company’s continued success and growth.”
About LAXAI
LAXAI is a US-based Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in small molecule solutions. The company provides comprehensive services to pharmaceutical, biotech, animal health, and specialty chemical industries, with expertise in complex process R&D, seamless project transitions from development to commercial-scale manufacturing, and both GMP and non-GMP production capabilities.
For more information, visit https://laxai.com/